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A full term, male patient was born in the UK to parents of Hazars ethnic background, 
weighing 3.5kg (50th percentile) and regaining his birth weight by day 12.  There was no 
significant family history and he had two healthy siblings.  He presented to hospital at five 
weeks of age with fever, respiratory distress, tachypnea, and CRP 59 (reference range, 
<5mg/L). Over the next six months he had a persistent cough and three further admissions. 
Chest radiographs showed persistent perihilar changes; he received multiple courses of 
antibiotics although tests for bacterial and viral infections were consistently negative. 
 
He was referred for specialist assessment at seven months of age with ongoing respiratory 
symptoms, intermittent fever and failure to thrive (weight 5.59kg, 0.4th percentile).  He was 
tachypneic with moderate respiratory distress, but normal oxygen saturations in room air. He 
had clusters of raised maculopapular, erythematous lesions on his neck, back, arm and legs 
first noted at five weeks of age (Figure 1A).  Some of the features of this case have been 
previously reported in the form of an abstract (Pellowe 2015). 
 
Initial investigations found CRP 10mg/L, microcytic anemia with mean cell volume 66.5fL 
(reference range, 68-84fL) and hemoglobin 100g/L (reference range, 111-141g/L).  White 
blood cell count, renal function, liver function, thyroid function and sweat chloride were 
normal.  Chest radiograph showed increased interstitial and peri-bronchial markings 
throughout both lungs. Chest computed tomography (CT) showed features of interstitial lung 
disease (ILD, Figure 1B). 
 
Immunological testing showed raised IgG (13.8g/L, reference range, 3.0-9.0g/L) and IgA 
levels (1.2g/L, reference range, 0.2-0.7g/L), abnormal lymphocyte proliferation, highly 
positive anti-nuclear antibody (ANA) screen with positive SS-A(Ro) and raised plasma 
  
viscosity (1.77 mPa.s, reference range, 1.50-1.72 mPa.s). Extensive investigations for 
bacteria, viruses and fungi were performed on peripheral blood, skin biopsy and 
bronchoalveolar lavage samples; all were negative.  
 
A lung biopsy showed active inflammation, with type II pneumocyte hyperplasia, epithelial 
hyperplasia of the bronchioles and surrounding lymphocytic infiltrate (Figure 1C).   
Ultrastructure examination with electron microscopy showed endothelial tuboreticular 
inclusions which are suggestive of excess type I interferon, either due due to exogenous 
treatment or endogenous overproduction (Figure 1D). 
 
Given the constellation of ILD, systemic inflammation and persistent rash since five weeks of 
age, a diagnosis of STING-associated vasculopathy with onset in infancy (SAVI) was 
considered.  Genetic analysis by Sanger sequencing confirmed a heterozygous somatic 
mutation (c.463G>A, p.V155M) in exon 5 of the TMEM173 (NM_198282.3), the gene 
encoding STING.  Genetic testing of the parents showed that the mutation had occurred de 
novo. Whole blood gene expression studies demonstrated a strong interferon signature, with 
interferon scores similar to other SAVI patients (Figure 2).  
 
Treatment with three days of intravenous methylprednisolone (10mg/kg) yielded no clinical 
improvement.  He gained weight with supplemental nasogastric feeding, but had persistent 
tachynpea, and subsequently became hypoxemic requiring low flow oxygen therapy. He then 
commenced monthly intravenous immunoglobulin (IVIg) at 2gms/kg; after four months of 
treatment there has been some clinical improvement, with reduced tachypnea and a stable 
oxygen requirement. 
 
  
The clinical syndrome of SAVI is characterized by early onset (<8 weeks of age) cutaneous 
vasculitis, fevers, ILD and systemic inflammation. On laboratory testing, common features 
include positive autoantibodies (particularly a persistently raised ANA), and raised IgG and 
IgA (Liu 2014); all features observed in our patient.  Our patient developed a more central 
rather than peripheral (ears, nose, digits) rash exacerbated by cold exposure more commonly 
seen in SAVI patients (Munoz 2015).   
 
Of the previously described cases, 11 out of 12 patients had clinically apparent lung disease 
(Liu 2014, Jeremiah 2015, Munoz 2015, Omoyinmi 2015).  Importantly, three of these 
patients have died in adolescence from pulmonary complications (Liu 2014, Omoyinmi 
2015).  Lung toxicity from exogenous type I interferon treatment has been reported in 
patients with multiple sclerosis (Petousi 2012, Chakravarty 2012) and chronic hepatitis C 
virus infection (Slavenburg 2010).  Despite the documented link between chronic type I 
interferon exposure and lung pathology, it is perplexing that SAVI is currently the only 
known type I interferonopathy where lung involvement is a common and major clinical 
feature.   
 
Autosomal dominant, gain-of-function mutations in the TMEM173 gene underlie the 
pathogenesis of SAVI.  TMEM173 encodes STING protein, an adaptor molecule linking 
sensing of foreign (viral and bacterial) DNA to the production of type I interferons as part of 
the innate immune response.  These gain-of-function mutations lead to constitutive activation 
of STING and upregulated type I interferon production.  STING is expressed in alveolar 
macrophages, bronchial epithelium and alveolar type II pneumocytes (Liu 2014) which 
presumably explains the specific lung pathology seen in SAVI. 
 
  
In addition, in vitro studies show STING also acts directly on endothelial cells, causing 
inflammation, and initiating the coagulation cascade.  Thus, these TMEM173 mutations are 
postulated to mediate chronic vessel endothelium inflammation leading to the vasculitic rash 
and vaso-occlusive processes seen in SAVI (Liu 2014). 
 
The predominance of early and significant respiratory symptoms, lack of characteristic 
peripheral rash in this patient and the variable phenotype described in family members with 
the same, inherited TMEM173 mutation (Jeremiah 2014) illustrates the variable phenotype of 
SAVI patients; further research into the genotype-phenotype correlation and prognosis is 
warranted.   
 
Treatment options in SAVI remain limited.  Liu et al reported a lack of response to 
glucocorticoids, disease-modifying anti-rheumatic drugs and biological therapies.  Isolated 
improvement in ILD has been documented in one patient following pulsed 
methylprednisolone and mycophenolate mofetil (Munoz 2015).  Given the pathogenesis in 
SAVI, there is potential benefit from Janus kinase (JAK) inhibitors to block type I interferon 
signaling despite constitutively activated STING.  The JAK inhibitor baricitinib has shown 
benefit in adult patients with a range of inflammatory conditions but there is limited 
paediatric data.  An approved clinical protocol to assess the therapeutic benefit of baricitinib 
in patients with either SAVI or chronic atypical neutrophilic dermatosis with lipodystrophy 
and elevated temperatures (CANDLE) interferonopathy is ongoing, and has recently 
published encouraging results in patients with CANDLE (ClinicalTrials.gov number, 
NCT01724580, Monteleagre 2015). 
  
  
To conclude, a diagnosis of SAVI has significant implications for patients and families, not 
only from the high mortality risk, but also the significant morbidity.  The respiratory 
component of the disease may predominate and pulmonary complications have been the 
cause of death in previous reports.  In the context of early age of onset, ILD, failure to thrive, 
fevers and rash, we urge respiratory pediatricians to consider SAVI as a differential diagnosis 
and to send testing for TMEM173 mutations and interferon gene signature to confirm the 
diagnosis. 
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Figure legends 
Figure 1: (A) Raised, papular, erythematous rash on the trunk.  (B) Chest CT scan showing 
widespread, slightly nodular interstitial opacification in both lungs.  There are a number of 
small (<1cm) peripheral cysts within the right lower and middle lobes. (C) Light microscopy 
microphotograph of lung biopsy (low magnification, hematoxylin and eosin stain), showing 
solid area composed of mixed infiltrate (left arrow) and chronic inflammation (right arrow). 
(D) Electron microscopy photograph of lung endothelium, showing tuboreticular inclusions 
(arrow). 
 
Figure 2:  Gene expression of selected interferon response genes (IRGs) were determined by 
Nanostring (NanoString Technologies, Seattle, WA) and an IFN-score was calculated for 
healthy controls, patients with varying autoinflammatory conditions and our patient (patient 
O6226). Standardized IFN score (y axis) is the sum of 6 Nanostring counts that were 
standardized by subtracting the mean of healthy controls and dividing by standard deviation 
of the healthy controls. IRGs assessed in this study were: IFI27, IFI44, IFI44L, ISG15, 
RSAD2 and USP18. Mean and standard deviation of the IFN score is depicted in parenthesis 
for each group of individuals. NOMID, neonatal onset multisystem inflammatory disease 
(mediated by excess IL-1); CANDLE, chronic atypical neutrophilic dermatosis with 
lipodystrophy and elevated temperature syndrome (mediated by excess IFN); SAVI, STING-
associated vasculopathy with onset in infancy (mediated by excess IFN). 
 
